Management of Elevated SGOT in First Trimester

Initial Diagnostic Workup

When SGOT (AST) is elevated in the first trimester, immediately exclude life-threatening conditions including hyperemesis gravidarum, acute fatty liver of pregnancy, and underlying chronic liver disease, then measure serum bile acids to rule out early-onset intrahepatic cholestasis of pregnancy, which requires genetic evaluation and multidisciplinary management 1, 2, 3
Measure serum bile acids immediately, as bile acid levels >40 μmol/L indicate increased risk of adverse pregnancy outcomes 1, 2

Total serum bile acids (TSBA) - non-fasting measurement, is essential for risk stratification and guiding management 1, 2, 3
Complete liver function panel including ALT, bilirubin, gamma-glutamyltransferase, and alkaline phosphatase, to exclude other liver diseases 1, 2
Autoimmune markers (AMA, ANA, SMA) to exclude autoimmune hepatitis, which may present with elevated transaminases 1, 2, 3

If TSBA >40 μmol/L, there is an increased risk of adverse outcomes, and consideration of induction at 39 weeks may be necessary 1, 2, 4
If TSBA >100 μmol/L, there is a markedly increased stillbirth risk after 35 weeks, and delivery should be planned at 36 weeks 1, 2, 4

Ursodeoxycholic acid (UDCA) is the first-line treatment for confirmed ICP with elevated bile acids, and should be continued throughout pregnancy and stopped at delivery 1, 3

Verify complete resolution of transaminase elevation and bile acids within 3 months of delivery, and refer to hepatology if abnormalities persist 1, 2, 3
Counsel about recurrence risk, as ICP recurs in up to 90% of subsequent pregnancies, and women with history of ICP have increased risk of later developing chronic hepatitis, liver fibrosis, hepatitis C, and cholangitis 4